How to appeal a Cigna inflammatory bowel disease (crohn's + uc) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for inflammatory bowel disease (crohn's + uc)

Cited policy: Cigna Entyvio (Vedolizumab) IV + SC for Crohn's + UC

Moderate-severe CD or UC. Documented inadequate response or intolerance to corticosteroids AND immunomodulator (AZA/6-MP/MTX) AND >=1 anti-TNF (or anti-TNF contraindication). IV induction wk 0/2/6 then 300 mg q8wk; SC maintenance 108 mg q2wk after wk 6. Reauth at 6 mo with clinical + biomarker response.

How Cigna denies inflammatory bowel disease (crohn's + uc) — and how to counter it

Where Cigna pushes back: 1) SC formulation not preferred — use IV; 2) Anti-TNF-naïve must try Humira first; 3) TB / HBV screening not on file.

Counter-arguments that hold up: Entyvio FDA-approved CD + UC May 20, 2014 (GEMINI 1 NEJM 2013;369:699; GEMINI 2 NEJM 2013;369:711; GEMINI 3 Gastro 2014). SC maintenance FDA UC Sep 2019 / CD Sep 2023 (VISIBLE-1 + VISIBLE-2). VARSITY (Sands NEJM 2019;381:1215) — vedolizumab SUPERIOR to adalimumab in UC head-to-head Phase 3 (clinical remission 31.3% vs 22.5%). AGA UC 2020 + CD 2020 list anti-integrin as parallel first-line. Patient preference + safety profile (gut-selective, low systemic immunosuppression) supports vedolizumab as biologic-naïve choice.

What Cigna typically denies for inflammatory bowel disease (crohn's + uc)

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For inflammatory bowel disease (crohn's + uc), expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the inflammatory bowel disease (crohn's + uc) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira (adalimumab)
• Remicade (infliximab)
• Cimzia (CD only)
• Simponi (UC only)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.